Search
NASH - Nonalcoholic Steatohepatitis Paid Clinical Trials in Utah
A listing of 4 NASH - Nonalcoholic Steatohepatitis clinical trials in Utah actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 4 of 4
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
NASH - Nonalcoholic Steatohepatitis
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Utah currently has 4 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies. These trials are conducted in various cities, including Salt Lake City, Murray, Ogden and West Jordan.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Trial
Norovirus Vaccine Clinical Study
Recruiting
We are actively recruiting patients who are interested in participating in a norovirus vaccine clinical trial. Eligible patients for this study may qualify if they are aged 60+ and willing to join a norovirus vaccine study.
Conditions:
Norovirus Vaccine
Norovirus
Norovirus Infections
Seniors
Aged 60 Years or Older
Featured Trial
COVID Vaccine Age 50-64 Study (Up to $710 Total Compensation)
Recruiting
Multiple COVID-19 investigational vaccine studies are now enrolling participants (Age 50-64), with appointments available. Participants who qualify may receive up to $710 in total compensation.
If eligible, participants may be matched to one of the current COVID-19 vaccine studies. Should you express interest, the study team will contact you directly to provide further details and answer any questions about study procedures, time commitment, potential risks/benefits, and compensation.
If eligible, participants may be matched to one of the current COVID-19 vaccine studies. Should you express interest, the study team will contact you directly to provide further details and answer any questions about study procedures, time commitment, potential risks/benefits, and compensation.
Conditions:
COVID Vaccine (Age 50-64)
COVID
COVID-19
COVID19
COVID 19
Featured Trial
COVID Vaccine (Age 50-64) Clinical Study
Recruiting
A clinical study for people that suffer with COVID Vaccine (Age 50-64)
Conditions:
COVID Vaccine (Age 50-64)
Healthy
Featured Trial
Vaccine (18+) Clinical Study
Recruiting
We are seeking healthy individuals aged 18 and above who are interested in participating in a vaccine clinical trial.
Conditions:
Vaccine (18+)
Healthy
Healthy Individuals
Healthy Volunteers
Healthy Subjects
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3).
The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/18/2025
Locations: Akero Clinical Study Site, Ogden, Utah +3 locations
Conditions: NASH With Fibrosis, MASH With Fibrosis
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Recruiting
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis \[NASH\]).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/03/2025
Locations: 89bio Clinical Study Site, Ogden, Utah
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Recruiting
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: 89bio Clinical Study Site, Sandy, Utah +1 locations
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Lone Peak Family Health, Draper, Utah +1 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
1 - 4 of 4